Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
140(c) 149(c) 153(c) 148(c) 147 Last
2 814 3 233 3 749 3 755 2 531 Volume
+6.06% +6.43% +2.68% -3.27% -0.68% Change
More quotes
Estimated financial data (e)
Sales 2019 3,58 M 0,54 M 0,54 M
Net income 2019 -18,8 M -2,86 M -2,86 M
Net cash position 2019 41,4 M 6,30 M 6,30 M
P/E ratio 2019 -5,54x
Yield 2019 -
Sales 2020 5,35 M 0,81 M 0,81 M
Net income 2020 -18,7 M -2,85 M -2,85 M
Net cash position 2020 33,5 M 5,10 M 5,10 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 469 M 71,3 M 71,3 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float 47,9%
More Financials
Company
ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis,... 
More about the company
All news about VIROGATES A/S
09:52aFRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
12/01ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
11/29NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
11/11Interim Report – Q1-Q3, 2021
PU
11/11VIROGATES ANNOUNCES ITS INTERIM REPO : Revenue growth of 66% for the first nine months of ..
AQ
11/11ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/11ViroGates announces a delay in the development and launch of its pipeline product suPAR..
AQ
11/11ViroGates A/S Announces Delay in the Development of suPARnostic? POC+
CI
11/10Invitation to ViroGates' Q3 2021 presentation
AQ
11/05Elevated preoperative suPAR is a strong and independent risk marker for postoperative c..
PU
10/25VIROGATES A/S : announces a new hospital as a clinical routine customer in Greece
AQ
10/25ViroGates A/S Announces New Hospital as Clinical Routine Customer in Greece
CI
10/21VIROGATES A/S : SuPAR is associated with risk for thromboembolic complications and mortali..
PU
10/14EVALUATION OF SUPAR LEVELS IN PATIEN : An observational cohort study
PU
09/17VIROGATES A/S : SuPAR measured using suPARnostic« TurbiLatex predicts critical illness and..
PU
More news
News in other languages on VIROGATES A/S

- No features available -

More news
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S81.60%71
EXACT SCIENCES CORPORATION-39.19%13 884
GUARDANT HEALTH, INC.-24.22%9 757
BGI GENOMICS CO., LTD.-27.85%5 963
ADAPTIVE BIOTECHNOLOGIES CORPORATION-55.64%3 702
INVITAE CORPORATION-62.31%3 568